FDA Watch: A New Blood Test for Accurate Alzheimer’s Detection
The ALZpath DX assay is less invasive than other diagnostic tests, and may give patients diagnosed with Alzheimer’s more time to plan
The ALZpath DX assay is less invasive than other diagnostic tests, and may give patients diagnosed with Alzheimer’s more time to plan
The FDA is adding International Organization for Standardization (ISO) guidelines to its “good manufacturing” requirements
G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.
First marketing authorization of a blood test assessing genetic variants related to cancer opens the door for clearance of similar tests.